Genotype and risk of major bleeding during warfarin treatment-Reference-Cited by-同舟云学术

Genotype and risk of major bleeding during warfarin treatment

Published:2014-12 Issue:16 Volume:15 Page:1973-1983
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Kawai Vivian K¹,Cunningham Andrew¹,Vear Susan I²,Van Driest Sara L³,Oginni Abimbola¹,Xu Hua⁴,Jiang Min⁴,Li Chun⁵⁶,Denny Joshua C⁷,Shaffer Christian⁷,Bowton Erica⁸,Gage Brian F⁹,Ray Wayne A¹⁰,Roden Dan M¹,Stein C Michael¹

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

2. Division of Hematology/Oncology & Blood Marrow Transplant Nationwide Children's Hospital, Columbus, OH, USA

3. Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA

4. School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA

5. Department of Epidemiology & Biostatistics, Case Western Reserve University, Cleveland, OH, USA

6. Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA

7. Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA

8. Vanderbilt Institute for Clinical & Translational Research, Vanderbilt University School of Medicine, Nashville, TN, USA

9. Division of General Medical Sciences, Washington University School of Medicine, St Louis, MO, USA

10. Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

Abstract

Aim: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. Materials & methods: Using Vanderbilt's DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases with major bleeding and 259 controls during warfarin therapy. Results: CYP2C9*3 was the only allele that differed significantly among cases (14.2%) and controls (7.8%; p = 0.022). In the 214 (85.6%) cases with a major bleed 30 or more days after warfarin initiation, CYP2C9*3 was the only variant associated with bleeding (adjusted odds ratio: 2.05; 95% CI: 1.04, 4.04). Conclusion: The CYP2C9*3 allele may double the risk of major bleeding among patients taking warfarin for 30 or more days.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.14.153

Reference42 articles.

1. National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011

2. Guidelines on oral anticoagulation with warfarin - fourth edition

3. Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism

4. Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation

5. Interindividual variability in sensitivity to warfarin-Nature or nurture?

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world evidence that among atrial fibrillation patients warfarin is associated with reduced nonelective admissions compared with those on DOACs;Clinical Cardiology;2023-09-08

2. A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with VariousCYP2C9Genotypes under Different Cotreatments;Drug Metabolism and Disposition;2022-11-15

3. Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model RevealsCYP2C9Genotype-Dependent Drug-Drug Interactions of S-Warfarin;Drug Metabolism and Disposition;2022-07-07

4. The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and ( S )‐Warfarin;Clinical Pharmacology & Therapeutics;2022-05-05

5. Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients;Drug Metabolism and Personalized Therapy;2022-04-04